Healthcare Providers and Services
Company Overview of Miraca Life Sciences, Inc.
Miraca Life Sciences, Inc. operates clinical pathology laboratories that provide diagnostic services in the fields of dermatology, gastroenterology, hematology, and urology in the United States. It focuses on the development of a blood-based diagnostics platform to address unmet clinical needs in the gastrointestinal cancer spectrum that range from screening and diagnosis to prognosis and therapeutic guidance. The company also provides urologic pathology services, including microscopy and immunohistochemistry with integrated molecular diagnostic services; EoGenius test that helps diagnose and monitor patients with eosinophilic esophagitis; and UroVysion, a deoxyribonucleic acid-based urine t...
6655 North MacArthur Boulevard
Irving, TX 75039
Founded in 1996
Key Executives for Miraca Life Sciences, Inc.
Chief Executive Officer and President
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2015.
Miraca Life Sciences, Inc. Key Developments
Miraca Life Sciences Launches the EoGenius™ Test
Mar 2 16
Miraca Life Sciences has launched the EoGenius™ test which helps diagnose and monitor patients with eosinophilic esophagitis (EoE). Exclusively offered by Miraca Life Sciences, the test helps clinicians differentiate between eosinophilic esophagitis and other clinical and pathologic mimics, such as GERD. Endoscopy of patient with eosinophilic esophagitis with characteristic rings and furrows. Details of the EoGenius test: The EoGenius test helps diagnose and monitor eosinophilic esophagitis; The assay panel comprises a 96-gene quantitative polymerase chain reaction array and an associated dual algorithm that uses cluster analysis and dimensionality reduction; Biopsy tissue from proximal, middle, or distal locations of the esophagus may be used; Formalin-fixed, paraffin-embedded tissue or RNA-later-preserved tissue may be used from a single biopsy; EoGenius has been validated in both adult and pediatric populations; The EoGenius report provides a result of Positive, Negative, or Indeterminate (approximately 10%), based on the gene expression score produced by the EoGenius algorithm. In clinical practice, differentiation is difficult between eosinophilic esophagitis and other common causes of esophageal eosinophilia, such as GERD, and other causes of dysphagia. Patients may have a mismatch between symptoms and histopathologic features, which creates a need for multiple assessments.
Theradiag Announces Strategic Licensing Agreement with Miraca Life Sciences
Nov 18 15
Theradiag announced a strategic licensing agreement with Miraca Life Sciences to offer in the United States Theradiag’s therapeutic drug monitoring assays, which are marketed in Europe and outside the United States under the LISA TRACKER brand name. Under the collaboration, Theradiag will grant MLS an exclusive know-how license for the validation, commercialization and promotion in the U.S. of therapeutic drug monitoring assays. It is estimated more than 330,000 IBD patients in the United States are treated with biologics1, two times more than in Europe. Theradiag estimates that the U.S. market could represent a major part of the future revenue of its Theranostic business unit. Under the agreement, MLS will conduct validation studies and market therapeutic drug monitoring tests throughout the U.S. via its specialized sales force. MLS also will promote therapeutic drug monitoring testing with key opinion leaders, laboratories and other advocates in the U.S. healthcare field. Under the terms of the agreement, Theradiag will receive an initial fee followed by additional payments if future tests are licensed. Theradiag will sell raw materials to MLS and will receive royalties on MLS’ sales in the U.S.
Miraca Life Sciences, Inc Formalizes and Expands Breast Pathology Business; Names Raheela Ashfaq as Director of Breast Pathology
Mar 31 15
Miraca Life Sciences has formalized and expanded its breast pathology offering, to include critical testing for both cancer risk and prognosis. Expansion includes new services for clinicians, including interventional radiologists, breast surgeons, and breast oncologists: Breast icon_cmyk. Miraca Life Sciences’ breast pathology services feature: Definitive diagnoses of breast conditions, consensus-based approach to terminology and diagnostic criteria, quantitative prognostic markers, heredity breast cancer panels, molecular tumor profiling, TNM (tumor, lymph nodes, metastasis) staging, and daily consensus conferences to review difficult cases and ensure the most definitive diagnoses. The expansion of the breast pathology offering is made possible in part by the capabilities provided by Baylor Miraca Genetics Laboratories, a joint venture of Miraca Holdings and the Baylor College of Medicine that was finalized last month.
Raheela Ashfaq, MD, has been named Director of Breast Pathology. She also serves on the scientific advisory board of Baylor Miraca Genetics Laboratories. Dr. Ashfaq has more than 20 years of experience in diagnosing breast conditions, both at Miraca Life Sciences and at University of Texas Southwestern Medical Center at Dallas. Previously as the Medical Director of Caris Life Sciences, she helped to launch molecular profiling for breast cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|